Amivantamab and lazertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with brain and leptomeningeal metastases: an editorial on efficacy, challenges in assessment, and future directions.
- DOI
- 10.21037/tlcr-2026-1035
- Published
- 2026-10-26
- Container
- Transl Lung Cancer Res
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.21037/tlcr-2026-1035,
title = {Amivantamab and lazertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with brain and leptomeningeal metastases: an editorial on efficacy, challenges in assessment, and future directions.},
author = {Nittur VR and Jo Y and Nagasaka M.},
year = {2026},
journal = {Transl Lung Cancer Res},
doi = {10.21037/tlcr-2026-1035},
url = {https://doi.org/10.21037/tlcr-2026-1035}
}RIS
TY - JOUR TI - Amivantamab and lazertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with brain and leptomeningeal metastases: an editorial on efficacy, challenges in assessment, and future directions. AU - Nittur VR AU - Jo Y AU - Nagasaka M. PY - 2026 JO - Transl Lung Cancer Res DO - 10.21037/tlcr-2026-1035 UR - https://doi.org/10.21037/tlcr-2026-1035 ER -
APA
VR, N., Y, J., & M., N. (2026). Amivantamab and lazertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with brain and leptomeningeal metastases: an editorial on efficacy, challenges in assessment, and future directions.. Transl Lung Cancer Res. https://doi.org/10.21037/tlcr-2026-1035
Source records
- europe-pmc · retrieved 2026-11-10T14:01:32.234Z